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Abstract
Background: Chromodomain-helicase-DNA-binding protein 5 (CHD5) is a newly identified tumor suppressor that is
frequently downregulated in a variety of human cancers. Our previous work revealed that the low expression of CHD5 in
colorectal cancer is correlated with CHD5 promoter CpG island hypermethylation. In this study, we investigated the effect of
microRNA-211 (miR-211)-regulated CHD5 expression on colorectal tumorigenesis.
Methodology/Principal Findings: miR-211 was predicted to target CHD5 by TargetScan software analysis. A stably
expressing exogenous miR-211 colorectal cancer cell line (HCT-116
miR-211) was generated using lentiviral transduction and
used as a model for in vitro and in vivo studies. The expression level of miR-211 in HCT-116
miR-211 cells was upregulated by
16-fold compared to vector control cells (HCT-116
vector). Exogenous miR-211 directly binds to the 39-untranslated region (39-
UTR) of CHD5 mRNA, resulting in a 50% decrease in CHD5 protein level in HCT-116
miR-211 cells. The levels of cell
proliferation, tumor growth, and cell migration of HCT-116
miR-211 cells were significantly higher than HCT-116
vector cells
under both in vitro and in vivo conditions, as determined using the methods of MTT, colony formation, flow cytometry,
scratch assay, and tumor xenografts, respectively. In addition, we found that enforced expression of miR-211 in HCT-116
cells was able to alter p53 pathway-associated regulatory proteins, such as MDM2, Bcl-2, Bcl-xL, and Bax.
Conclusion/Significance: Our results demonstrate that CHD5 is a direct target of miR-211 regulation. Enforced expression of
miR-211 promotes tumor cell growth at least in part by downregulating the expression level of the CHD5 tumor suppressor.
Our results provide a better understanding of the association of between miR-211-regulated CHD5 expression and CHD5
function in colorectal tumorigenesis.
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Introduction
Identifying cancer-related genes and understanding their
contribution to tumorigenesis are critical steps in controlling
cancer. Recent studies have demonstrated that gene expression
can be affected by changes in chromatin structure and the
association of DNA with nucleosomes [1]. For example, Swi/Snf
proteins can cause ATP-dependent disruption of nucleosome
structure at a promoter, which enhances the binding of
transcription factors to their binding sites [1]. The actions of
these proteins can also lead to nucleosome movement and changes
in chromatin conformation, resulting in profound transcriptional
activation (or repression) of a gene or region [1].
Chromodomain-helicase-DNA-binding genes (CHD) encode a
novel class of Swi/Snf proteins that not only contain a Swi/Snf-
like helicase ATPase domain but also additional functional
domains [2,3]. These proteins have a DNA-binding domain as
well as a chromodomain motif that can directly effect chromatin
structure and gene transcription. There is increasing evidence that
CHD protein complexes can have a profound effect on chromatin
structure and gene expression. Therefore, it is likely that they play
an important role in regulating development, cell cycle control,
and oncogenesis [4]. CHD is a super family that can be subdivided
into five subfamilies based on the presence of specific protein
motifs, which endow each family of proteins with a unique
function. CHD5 is most similar to CHD3 and CHD4 in that it is
contains plant homeodomain motifs. CHD5 was recently
identified as a novel tumor suppressor that maps to 1p36, which
is frequently deleted in many types of human cancers [5,6], and the
chromatin-remodeling activity of CHD5 is required for appropriate
transcriptional activation of the p19
Arf/p53 pathway [7].
It is clear that CHD5 deficiency is a common initiating event in
human tumorigenesis. CHD5 is frequently downregulated through
promoter hypermethylation in gastric, breast, ovarian, and glioma
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29750tumors [8,9,10,11], suggesting epigenetic silencing of CHD5 by
methylation may contribute to tumorigenesis in these tissues.
Colorectal cancer (CRC) is one of the three most prevalent cancers
in the United States [12] and CHD5 is frequently hypermethy-
lated in human colon cancer cell lines and primary tumors
[2,13,14].
Although there are many studies on the methylation status of
CHD5 in different types of tumors, there are few studies on how
another important epigenetic mechanism, microRNAs (miRNAs),
may also play a critical role in CHD5 deficiency during colorectal
tumorigenesis. miRNAs are small, non-coding RNA molecules
present in animals, plants, and viruses that are primarily involved
in gene silencing by imperfect base pairing with the 39-
untranslated regions (39-UTR) of specific mRNAs, which induces
mRNA degradation [15]. The loose binding constraints allow one
miRNA to bind to several sites within one 39-UTR and to multiple
mRNA targets within the transcriptome, endowing miRNAs with
the ability to inhibit several genes at once [16]. Many miRNAs are
conserved across widely diverse phyla, indicating their physiolog-
ical importance [15]. miRNAs play a key role in regulating diverse
cellular processes, including development, differentiation, cell
growth, apoptosis, viral infection, and metabolism [17].
Some of the miRNAs that are dysregulated in cancer function as
tumor suppressors or oncogenes [18]. Several such miRNAs have
been identified in colorectal cancer, including the upregulated
miR-31, miR-96, miR-135b, and miR-183 and the downregulated
miR-133b and miR-145 [19]. Since miRNAs bind the 39-UTR of
their target mRNAs by base pairing, the region of complemen-
tarity between a miRNA and its mRNA target is small. This region
encompasses nucleotides 2–7 from the 59-end of the miRNA and is
referred to as the ‘seed’ region [20]. Different computational
approaches have been developed to predict miRNA target sites
throughout the genome [21]. By using the informatic tools
MiRanda, PicTar, and TargetScan, miR-211 was predicted to
base pair with the 39-UTR of CHD5, but in vitro and in vivo
experiments are necessary to confirm whether miR-211 actually
targets CHD5.
In the present study, we investigated the role of miR-211 on
colorectal cancer cells through its downregulation of CHD5 in vitro
and in vivo. First, we examined the expression levels of miR-211
and CHD5 in the colorectal cancer cell lines RKO and HCT-116.
We then selected HCT-116 and established the miR-211-stably
transfected cell line HCT-116
miR-211. Finally, we used this cell line
to perform a series of in vitro and in vivo experiments in order to
determine whether miR-211 targets CHD5.
Results
Expression levels of CHD5 protein and miR-211 are
inversely correlated in human colon cancer cell lines
miR-211 was chosen as a candidate miRNA for targeting
CHD5 due to its imperfect base pairing to the 39-UTR of CHD5
(Fig. 1A). We investigated the expression level of miR-211 in these
two cell lines by quantitative real-time RT-PCR (Fig. 1B). In order
to select the appropriate cell lines for our study, we evaluated the
level of CHD5 protein in four colon cancer cell lines by Western
blot analysis (Fig. 1C), which included two previously established
cell lines (RKO and HCT-116) and two CHD5 transfected cell
lines (RKO-S and RKO-AS). Our results revealed that HCT-116
had the highest expression of CHD5 and RKO had the lowest
expression of CHD5. Therefore, HCT-116 and RKO cells lines
were used for subsequent experiments. We found an inverse
correlation of CHD5 and miR-211 expression (Fig. 1D). The
expression level of CHD5 in HCT-116 was 4-fold higher than in
RKO, while the expression level of miR-211 in HCT-116 was
only 20% of that in RKO. Since HCT-116 cells had both the
highest expression level of CHD5 and lowest expression level of
miR-211, this cell line was chosen as a candidate cell line to stably
Figure 1. Comparison of CHD5 and miR-211 expression in various colorectal cancer cell lines. (A) RNA sequence map of the 39-UTR of
CHD5 (Gene ID 26038) mRNA with the complementary site (39-UTR 130–136) for the seed region of miRNA-211. (B) miR-211 levels in RKO, HCT-116,
RKO-S, and RKO-AS cell lines by quantitative RT-PCR based on miR-211/U6 expression fold values. (C) CHD5 protein levels in two colon cancer cell
lines (RKO and HCT-116) and two established cell lines (RKO-S and RKO-AS) with enforced CHD5-S expression were analyzed by Western blot and
semi-quantified based on CHD5/b-actin relative intensities. Bio-Rad Quantity One software was used for densitometric analysis of the Western blots.
(D) Comparison of CHD5 and miR-211 expression levels in HCT-116 and RKO cell lines. * indicated as P,0.05.
doi:10.1371/journal.pone.0029750.g001
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of miR-211 in the regulation of CHD5 expression under cell
culture and tumor xenograft conditions.
Stably enforced expression of miR-211 directly
downregulates CHD5 protein levels in HCT-116 cells
In order to investigate the role of miR-211 in the downregu-
lation of CHD5 under cell culture conditions, we constructed a
HCT-116 cell line that stably expressed miR-211 using a
lentiviral-delivery system to insert an expression cassette with a
PCMV promoter, EGFP, and miR-211 precursor (Fig. 2A). We also
constructed a HCT-116 cell line, HCT-116
vec, that stably
expressed the GFP control vector. Fourteen days after lentiviral
infection, nearly all HCT-116 cells had detectable levels of green
fluorescence, which is an indicator of efficient infection. The
lentiviral-delivered EGFP-miR-211 expression was quantified by
real-time RT-PCR. miR-211 expression in HCT-116
miR-211
increased by 16-fold (p,0.05). In addition, the expression level
of CHD5 decreased significantly (Fig. 2B), with the protein level of
CHD5 in HCT-116
miR-211 cell at only 50% of that in HCT-116
vec
cells (Fig. 2C). In addition, CHD5 was confirmed as a direct target
of miR-211 by a luciferase reporter assay. Fluorescence activity
decreased over 90% after 293T cells were co-transfected with the
miR-211 expression vector and 39-UTR of CHD5 mRNA
luciferase reporter vector compared to the 39-UTR of CHD5
luciferase reporter vector alone (Fig. 2D).
Enforced miR-211 expression increases the proliferation
and migration of colon cancer cells in vitro
The effect of miR-211 on cell proliferation was assessed using a
colorimetric formation assay and cell viability was measured using
the MTT assay. HCT-116
vec and HCT-116
miR-211 cells were
seeded in separate 6-well plates and cell growth was monitored
daily under a microscope for ten days until the colonies were
clearly visible to the naked eye. As expected, HCT-116
miR-211 cells
displayed significantly increased proliferation, leading to the
formation of more colonies. The colony forming ability of HCT-
116
miR-211 cells was 221% (p,0.05) more than that of HCT-116
vec
cells (Fig. 3A). The MTT assay showed that enforced expression of
miR-211 in HCT-116
miR-211 cells led to a 30% increase in cell
proliferation compared to HCT-116
vec cells (Fig. 3B). The cell
cycle measurements by FCM showed that the proportion of cells
in G1 phase decreased by 53% (p,0.05), and that in S phase
increased by 51% (p,0.05) in HCT-116
miR-211 cells, respectively,
compared to HCT-116
vec cells (Fig. 3C, D). We also tested the
effect of miR-211 on cell migration by scratch assay (Fig. 4A). We
found that enforced miR-211 expression significantly increased the
potential of HCT-116 cells to migrate when compared to the
Figure 2. miR-211 inhibits CHD5 expression in colorectal cancer cells stably expressing exogenous miR-211. (A) Schematic
representation of the miR-211 vector, which contains an expression cassette of the PCMV promoter, EGFP, and miR-211 precursor and a selective
cassette of the PPGK promoter and Puro
r. (B) CHD5 protein levels in cell lines HCT-116
vec and HCT-116
miR-211 were evaluated by Western blot and (C)
semi-quantified based on CHD5/b-actin relative intensities. (D) Luciferase reporter assay using HEK 293T cells that were transfected with either the
luciferase/39-UTR miR-211 reporter vector, the miR-211 vector, or both. Schematic representation of the luciferase-CHD5 reporter vector and
luciferase reporter control vector were also inserted. * indicated as P,0.05.
doi:10.1371/journal.pone.0029750.g002
miR-211 Inhibits CHD5 Expression
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29750control cells. The HCT-116
miR-211 cells were notably migrated
into the scratch area at the reference time 5 hr, and the cells were
almost crossed over the scratch area at the time 24 hr (Fig. 4A).
There was approximately 42.2% more cells in the scratch area of
HCT-116
miR-211 cell plate than HCT-116
vec cells (Fig. 4B).
Enforced miR-211 increases the proliferation of colon
cancer cells in vivo
In addition to examining the biological functions of miR-211 in
vitro, we also assessed the in vivo function of miR-211 using a
xenograft transplantation model. By subcutaneously transplanting
the HCT-116
vec or HCT-116
miR-211 cells into nude mice, we
monitored tumor growth over a 6-week period. As shown in
Figure 5, after 6 weeks a solid tumor had formed in the right flank
of each of the mice with the average size of 284 mm
3 and an
average weight of 0.592 g. However, much smaller tumors were
formed in the left flank with an average size of 13.55 mm
3 and an
average weight of 0.028 g, suggesting that miR-211 increases the
proliferation of colon cancer cells in vivo.
Enforced expression of miR-211 alters the expression of
growth-associated proteins and p53-related pathway
proteins
The expression levels of the cell survival-supporting proteins
Bcl-2 and Bcl-xL in HCT-116
miR-211 were increased by 37% and
29%, respectively, while the expression level of the death-
promoting protein Bad was decreased by 22% (Fig. 6A, B).
Expression of Mdm-2, a negative regulator of p53, was increased
33% in HCT-116
miR-211 cells compared to HCT-116
vec cells.
However, expression of p53 and its target gene Bax decreased by
18% and 51%, respectively (Fig. 6C, D).
Discussion
CHD5 is a newly identified tumor suppressor gene [2] located
at 1p36 [7]. Its reduced expression occurs in many tumor types
due to hypermethylation of its promoter [8,9,11]. Several studies
have suggested that CHD5 positively regulates p53-mediated
pathways. The downregulation and hypermethylation of CHD5
has been found in CRC [2,13,15]. However, little is known
regarding whether miRNAs, another aspect of epigenetic
regulation, impact CHD5 expression and the phenotype of CRC
cells.
MiRNAs are predicted to regulate over 30% of all gene
expression and may account for some of the aberrant gene
expression in cancer cells. We used bioinformatic tools and found
that miR-211 is predicted to base pair to the 39-untranslated
region (39-UTR) of CHD5 (Fig. 2A). miR-211 is significantly
upregulated in other types of cancer [22] and may function as an
oncogene, which is consistent with the tumor suppressor function
of CHD5. However, whether miR-211 directly targets CHD5 and
Figure 3. Exogenous miR-211 potentiates proliferation and growth of colorectal cancer cells in vitro. Cell proliferation and cell viability
of cultured HCT-116
vec and HCT-116
miR-211 cell lines were compared using (A) colony formation assay, (B) MTT assay,and (C and D) cell cycle profiles
and the distribution of cells in G1, S, and G2-M phases for each group were analyzed by flow cytometry. The results represent the mean 6 SD of two
independent experiments with triplicates and * indicated as P,0.05.
doi:10.1371/journal.pone.0029750.g003
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confirmed. In the present study, we determined that enforced
expression of miR-211 in a colorectal cancer cell line directly
downregulates CHD5, resulting in increased cell viability, cell
cycle progression, and migration ability and decreased apoptosis.
We confirmed our results at several different levels, including cell
culture, tumor xenografts, and protein changes in CHD5-related
pathways.
We successfully established a colon cancer cell line that stably
expressed EGFP-miR-211, HCT-116
miR-211, using stable gene
transfection technology (Fig. 2A). RKO and HCT-116 are both
colorectal cancer cell lines. CHD5 was lowly expressed in RKO
and highly expressed in HCT-116 cells [14]. The expression levels
of CHD5 and miR-211 in RKO, RKO-S, RKO-AS, and HCT-
116 were detected by Western blot and real-time PCR. While
RKO-S is CHD5-stably transfected cell line, HCT-116 had the
highest expression level of CHD5. Since HCT-116 also had the
lowest expression level of miR-211, we selected this cell line to
stably transfect with miR-211 (Fig. 1D). We successfully
established enforced EGFP-miR-211 expression in the colon cell
line HCT-116
miR-211 using the Lenti-X
TM Lentiviral Expression
System. We also established a cell line transfected with the empty
EGFP vector, HCT-116
vec. Since the EGFP gene shared the same
PCMV promoter with the miR-211 gene, we were able to easily
monitor miR-211 expression in the cells under a fluorescent
microscope. Since the expression of miR-211 in HCT-116 and
HCT-116
vec cells was similar, HCT-116
vec was used as the control
cell line for the following experiments. The expression level of
miR-211 was 15-fold higher in HCT-116
miR-211 cells compared to
HCT-116
veccells.
In addition, the level of CHD5 expression was significantly
reduced in HCT-116
miR-211 cells compared with HCT-116
vec cells
(Fig. 2B, C). Enforced expression of miR-211 in HCT-116 cells
increased proliferation, colony formation, viability (Fig. 3), and
migration ability (Fig. 4) in vitro. Cell transit from G0/G1 to S
phase was accelerated (Fig. 3C,D) and expression of cell survival-
supporting proteins Bcl-2 and Bcl-xL increased while expression of
the death-promoting protein Bad decreased (Fig. 6A,B). Upregula-
tion of miR-211 enhanced the proliferation of colorectal cancer
cells may be by downregulating CHD5 (Fig. 2D) and also
Figure 4. Effects of exogenous miR-211 on the migration ability of colorectal cancer cell lines. (A) The scratched open areas were
observed at hours 0, 5, 8, and 24 for HCT-116
vec and HCT-116
miR-211 cell lines under a light microscope at 6400 magnification. (B) The cells were
counted from the various time period in the same size of scratch area as referenced at time 0 hr. The results of the scratch assay were from two
independent experiments with triplicates and * indicated as P,0.05.
doi:10.1371/journal.pone.0029750.g004
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transplantation of HCT-116
miR-211 and HCT-116 cells into nude
mice, HCT-116
miR-211 developed into tumors with an average
weight of 0.592 g while HCT-116 cells only formed much smaller
tumors with an average weight of 0.028 g. Taking into accounts
that HCT-116 and HCT-116
vec didn’t show any significant
differences in biological behavior, our results reveal that miR-211
promotes tumor growth of xenografts in vivo (Fig. 5).
Interestingly, downregulation of CHD5 by miR-211 impacts the
phenotype of colorectal cell line by affecting the expression of p53-
related pathway proteins (Fig. 6C, D). p53 is one of the most
studied tumor suppressors and over 50% of human tumors carry
loss of function mutations [23]. p53 suppresses tumorigenesis
through the induction of cell-cycle-arrest or apoptosis programs in
response to a plethora of different cellular stress signals [24]. The
tumor suppressor function of p53 also includes other mechanisms,
including regulating metabolic pathways [25]. CHD5 appears to
modulate carcinogenesis through a p53-related pathway [7]. In
our study, we found that upregulation of miR-211 in HCT-116
cells resulted in downregulation of CHD5, affecting the expression
of several p53-regulated pathway proteins, including Mdm-2, p53,
and Bax. The level of Mdm-2, a negative regulator of p53, was
increased while the levels of p53 and its target gene, Bax, were
decreased, indicating that CHD5 deficiency compromises p53-
regulated pathways and facilitates tumorigenesis. The malignant
phenotype of the HCT-116 cells was increased by upregulation of
miR-211 and the enhancement of proliferation and migration of
HCT-116 cells may be involved subsequent alterations in p53-
related pathways. Further studies will be needed to determine
whether p53-related signaling is the sole target for miRNA-211
regulation of CHD5.
Taken together, the aberrant expression of miR-211 and
subsequent change in the level of CHD5 are associated with
colorectal tumorigenesis. Our results demonstrate that enforced
expression of miR-211 in the colorectal cancer cell line HCT-116
increased the malignant phenotype of the cells by directly
downregulating the expression of CHD5 and may be by
modulating p53-related pathways. Specifically, enforced expres-
sion of miR-211 enhanced promotion and migration, reduced
apoptosis, accelerated the transition from G0/G1 to S phase in
vitro and enhanced proliferation in vivo. However, since one single
miRNA can modulate several different targets the other possible
roles of miR-211 in colorectal cancer need further study. In
addition, more studies are needed to validate the relationship
between miR-211 and CHD5 in human colorectal cancer
development and prognosis. Our study provides a better
understanding of regulatory capacity of the miR-211 in promoting
colorectal tumorigenesis by targeting CHD5 expression.
Materials and Methods
Cell lines and culture
Human colon cancer cell lines (RKO and HCT-116) and a
human embryonic kidney cell line (HEK293T) were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA, USA). We used two CHD5-Sens and CHD5-antiSens forced
expression stably established RKO cell lines (CHD5 upregulated
cell line RKO-S and its anti-sense RKO-AS) [26]. RKO cells were
cultured in MEM and RKO-S and RKO-AS cells were cultured
in MEM containing 900 mg/ml G418. HCT-116 cells were
cultured in McCoy’s 5A medium (ATCC). HEK293T cells were
cultured in Dulbecco’s Modified Eagle’s medium (DMEM; Gibco,
USA). All media was supplemented with 10% fetal bovine serum
and 1% Penicillin/Streptomycin, and all cell lines were main-
tained at 37uCi n5 %C O 2 and 95% humidity.
Identification of microRNA targets
The algorithms of MiRanda (http://www.sanger.ac.uk), Pic-
Tar (http://pictar.bio.nyu.edu), and TargetScan (http://www.
targetscan.org/) were used to predict which human miRNAs may
bind to the 39-UTR of CHD5 (Gene ID 26038). Briefly, these
algorithms provide 39-UTR alignments with predicted sites and
links to various public databases for the prediction of miRNA
binding sites.
miRNA extraction and quantitative RT-PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen,
Germantown, MD, USA). A miR-211 forward primer (59-
TTCCCTTTGTCATCCTTCGCCT-39) was synthesized at
Sigma (Woodlands, TX). Total RNA was polyadenylated by
polyA polymerase from E. coli, and then first-strand cDNA
synthesis and quantitative PCR were conducted with the High-
Specificity miRNA QRT-PCR Detection kit (Stratagene, La Jolla,
CA). Polymerase chain reaction (PCR) was performed on a
Mx3000P
TM Instrument (Stratagene Laboratory), with U6 as an
internal control because of its stable expression across human
tissues and cell lines, as suggested by the manufacturer and other
investigators [27]. We used the comparative threshold cycle (Ct)
method to measure relative changes in miRNA expression. Ct is
Figure 5. Exogenous miR-211 potentiates proliferation and
growth of colorectal cancer cells in vivo. (A) Tumor xenograft
growth of HCT-116 and HCT-116
miR-211 are shown under a light and
fluorescence imaging system. The tumor mass (g) was measured on the
final experimental day immediately after the tumor tissue was removed
from the mouse by surgical excision. Tumor xenograft growth for HCT-
116 and HCT-116
miR-211 groups was compared. (B) The day of cell
inoculation was the experimental start day and all mice were sacrificed
on day 43. The growth of solid tumor xenografts was monitored once a
week and measured using vernier calipers.
doi:10.1371/journal.pone.0029750.g005
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amplification plot passes a fixed threshold. DCt=Ct(miR-
211)2Ct(U6), DDCt=DCt(vector)2DCt (miR-211). Expression
fold value=2
2DDCt. All experiments were done in triplicate. A
negative control without a template was run in parallel to assess
the overall specificity of the reaction.
Stable transfection of miR-211
We modified the commercial pLVX-Tight-Puro vector (Clon-
tech, Mountain View, CA) with an expression cassette containing
the PCMV promoter, EGFP, miRNA linker, and pre-miR-211 by
replacing the Ptight promoter [28]. The miRNA linker contained a
multiple cloning site. The pre-miR-211 double strand sequence was
designed based on miRBase Sequence database version 12.0. The
constructed vectors were verified by DNA sequencing. The
recombinant lentiviral particles containing either the miR-211
vector or the EGFP control vector were transfected into HEK 293T
packaging cells using the lentiphos
TM HT packaging system and
following the manufacturer’s instructions (Clontech, Mountain
View, CA). HCT-116 cells were grown to 70–80% confluence in 6-
well plates and infected with 200 ml of lentivirus containing either
the miR-211 vector or the control vector for 2 h. Afterwards, 2 ml
of McCoy’s 5A media with 10% FBS was added to each well. After
48 h, the infected cells were selected with fresh medium containing
5 mg/ml puromycin for 4–5 passages. Cell lines stably expressing
either miR-211 or the control vector were generated and the
infected cells could be viewed under a fluorescence microscope.
Luciferase reporter assay
A luciferase reporter assay was used to verify that the
complementary sequence of miR-211 binds to the 39-UTR of
CHD5 mRNA. A fragment of CHD5 mRNA, which included
miR-211’s binding site was cloned into the phCMV-FSR
luciferase reporter vector (Genlantis, San Diego, CA). HEK
293T cells were seeded in a 24-well plate so that they were 50%
confluent at the time of transfection. The luciferase reporter vector
and either the GFP control vector or miR-211 expression vector
were cotransfected in HEK 293T cells using calcium phosphate
precipitation. Luciferase activity was measured in live cells 48 h
later according to the manufacturer’s protocol using biolumines-
cence imaging with a Xenogren IVIS instrument (Caliper Life
Sciences, Hopkinton, MA).
3-(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyltetrazolium
bromide (MTT) assay
An MTT assay was performed as previously described [29].
Briefly, cells were seeded into 96 well plates at an initial density of
5,000 cells/well. After 72 h, 200 ml of MTT solution (5 mg/mL,
Sigma, St Louis, MO) was added to each well and incubated for
4 h at 37uC. The supernatant was then discarded, and 200 mlo f
dimethyl sulfoxide (DMSO) was added to each well to dissolve the
precipitate. After 30 min at room temperature the plates were
scanned spectrophotometrically with a microplate reader (Bio-
Rad, Hercules, CA) set at 560 nm to measure the absorbance.
Each test was repeated in five wells.
Figure 6. Effects of exogenous miR-211 on cell growth-associated proteins and p53-related pathway proteins in colorectal cancer
cell lines. (A) The levels of cell growth-associated proteins in HCT-116
vec and HCT-116
miR-211 cell lines were analyzed by Western blot and (B) semi-
quantified based on targeted protein/b-actin relative intensities. The levels of p53-related pathway proteins in HCT-116
vec and HCT-116
miR-211 cell
lines were analyzed by Western blot (C) and semi-quantified based on targeted protein/b-actin relative intensities (D).
doi:10.1371/journal.pone.0029750.g006
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A colony formation assay was performed as previously described
[29]. Briefly, HCT-116
vec and HCT-116
miR-211 cells were plated
into 6-well tissue culture plates (Palo Alto, CA). Five hundred cells
of HCT-116
vec and HCT-116
miR-211 were seeded into each well in
triplicate, incubated for 10 days, and colonies were stained with
0.1% trypan blue in 50% ethanol. Colonies containing 50 or more
cells were counted as viable clonogenic cells. At least two
independent experiments were performed.
Cell cycle assay
Cell cycle analysis was performed as previously described [29].
Briefly, HCT-116
vec and HCT-116
miR-211 cells in the log phase of
growth were collected and fixed with cold 75% ethanol and stored
at 220uC for 24 h. After the ethanol was removed, the cells were
incubated with 1 mg/ml RNase A in PBS for 30 min at room
temperature, and then the cells were incubated an additional
30 min in the dark in 0.5 ml of 50 mg/ml propidium iodide. The
distribution of cells throughout the cell cycle was analyzed by
Becton-Dickinson FACScan, and DNA histograms were analyzed
with modified software. Each test was repeated in triplicate.
The scratch assay
Briefly, an open area or ‘scratch’ was produced in 90% HCT-
116
miR-211 cell monolayers using a 200 ml pipette tip as previously
described [30]. HCT-116
miR-211 cells were washed with PBS to
remove the displaced cells in the open area, and cultured in
McCoy’s 5A for designated times. HCT-116
vec were similarly
treated and cultured in McCoy’s 5A. Migration into the open area
was observed by the naked eye.
Western blot analysis
HCT-116
vec and HCT-116
miR-211 cells were washed with cold
PBS and lysed in RIPA lysis buffer on ice for 30 min.
Homogenates of cells were clarified by centrifugation at
16,000 g for 30 min at 4uC and the protein concentration was
measured using Quick Start Bradford Dye Reagent (Bio-Rad).
Forty mg of protein from each sample was subjected to SDS-PAGE
on an SDS-acrylamide gel. The separated proteins were
transferred to PVDF membranes and incubated with a primary
antibody followed by incubation with a secondary antibody. The
specific protein was detected using Bio-Rad equipment (Thermo
Spectronic Company). Primary antibodies used for Western blot
analysis included rabbit anti-human CHD5 (Abcam; 1:5,000
dilution), mouse anti-human Bcl-2 (Sigma; 1:1,000 dilution), rabbit
anti-human Bcl-xL (Sigma; 1:1,000 dilution), rabbit anti-human
Bad (Santa Cruz; 1:500 dilution), rabbit anti-human Bax (Sigma;
1:500 dilution), rabbit anti-human p53 (Sigma; 1:1,000 dilution),
mouse anti-human MDM-2 (Sigma; 1:1,000 dilution), and mouse
anti-human b-actin (Sigma; 1:5,000 dilution) and secondary
antibodies included goat anti-rabbit IgG-HRP (Santa Cruz;
1:2,000 dilution) and goat anti-mouse IgG-HRP (Santa Cruz;
1:2,000 dilution). Mouse anti-human b-actin was used as a control.
In vivo xenograft tumor growth in nude mice
The in vivo test was performed as previously described [29].
Four-week-old, male Balb/c athymic nude mice (Nu/Nu) were
obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN).
Mice were housed in temperature-controlled rooms (7462uF) with
a 12-hour alternating light-dark cycle. Approximately 3610
6 cells
in log phase were resuspended in McCoy’s 5A medium and
injected subcutaneously into the mice. To minimize individual
differences, HCT-116 cells and HCT-116
miR-211 cells were
injected into the left and right flanks of each mouse, respectively.
The six mice were housed for 6 weeks post inoculation. The mice
were euthanized and the tumor tissues were removed by surgical
excision. Tumor volume was measured once a week during the
experimental period. Guidelines for the humane treatment of
animals were followed as approved by the Howard University
Animal Care and Use Committee (IACUC MED 10-10 R3).
Statistical analysis
Data are expressed as the mean 6 standard deviation (S.D.).
p,0.05 was considered statistically significant for ANOVA and
STD t tests.
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